How to Buy Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
Ionis Pharmaceuticals stock last closed at $83.88, up 2.39% from the previous day, and has increased 155.11% in one year. It has overperformed other stocks in the Biotechnology industry by 1.89 percentage points. Ionis Pharmaceuticals stock is currently +250.23% from its 52-week low of $23.95, and -2.63% from its 52-week high of $86.15.
At the moment, there are 161.97M IONS shares outstanding. The market capitalization of IONS is $13.59B. In the past 24 hours, 1.63M IONS shares were traded.
How to Buy Ionis Pharmaceuticals Stock
Wondering how to invest in Ionis Pharmaceuticals stock? Here's how.
- Figure out where to buy Ionis Pharmaceuticals stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you determine where to buy Ionis Pharmaceuticals stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Choose your method of payment and add your details.
- Research Ionis Pharmaceuticals stock: The Ionis Pharmaceuticals ticker symbol is IONS. Is Ionis Pharmaceuticals stock a good investment? Should you buy shares of IONS? How do IONS's underlying business fundamentals look? Do top analysts think Ionis Pharmaceuticals is a good buy? Why has IONS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if IONS is a good stock to buy).
- Execute your IONS buy order: Decide if you will purchase IONS shares at the current market price or use a limit order to purchase IONS stock at a specific price.
- Get the latest news on your investment in IONS: Create a watchlist to the latest updates on your investment in Ionis Pharmaceuticals stock.
Step 1: Figure out where to buy Ionis Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy IONS shares.
Our recommended brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal information so you can invest in IONS today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open a new brokerage account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on the best stock app, your next step is to transfer the money for your investment:
Check out the walkthrough below to see the process of transferring money into your new brokerage account.
Step 4: Research Ionis Pharmaceuticals stock
Once you have decided on the best place to buy Ionis Pharmaceuticals stock, it's absolutely critical to evaluate their stock prior to investing, so you actually comprehend the risk and opportunity.
Ionis Pharmaceuticals quick stats
Ionis Pharmaceuticals Fundamentals
WallStreetZen was created to help average investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on IONS's stock page.
How is IONS stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge IONS's fair value.
Using relative valuations ratios:
- IONS could be overvalued based on its P/B ratio of 21.99x, relative to Biotechnology industry P/B ratio of 5.51x
You can access additional valuation research on IONS's stock here.
IONS Financials at a glance
Signs that IONS is financially healthy:
- There are more short-term assets than long-term liabilities on the IONS balance sheet.
- There are more short-term assets than short-term liabilities on the IONS balance sheet.
- IONS has cash burn of 302662000. It has sufficient cash and short-term investments to cover this for at least one year.
- IONS has $2.24B in cash and short term investments. This is sufficient to cover its annual cash burn of $302.66M.
Signs that IONS is not financially healthy:
- IONS profit margin has gone up by 0.18 percentage points in the past year, but the company is still unprofitable.
- IONS has a relatively high debt to equity ratio of 3.91.
- Total IONS debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy Ionis Pharmaceuticals stock
Out of 21 Equities analysts who track IONS, the consensus analyst rating on IONS is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Most Recent IONS Analyst Recommendations
Allison Bratzel, a top 7% analyst from Piper Sandler maintains IONS with a strong buy rating and raises their IONS price target from $70.00 to $77.00, on Nov 4, 2025.
Piper Sandler's Allison Bratzel raised their price target on Ionis Pharmaceuticals (NASDAQ: IONS) by 10% from $70 to $77 on 2025/11/04. The analyst maintained their Strong Buy rating on the stock.
Ionis Pharmaceuticals reported its Q3 2025 earnings.
The company delivered a robust print, with $157M in sales, including $32M from Tryngolza, Bratzel told readers.
The analyst said they are pleased with Ionis Pharmaceuticals' recent business performance and still bullish on the stock, citing the potential for portfolio growth in the short and intermediate terms across owned and partnered assets.
Earnings Report
For Q3 2025, Ionis Pharmaceuticals reported:
- EPS of $(0.61), which beat the Zacks Consensus Estimate of $(1.15) and Q3 2024's $(0.72).
- Revenue of $157M, which beat the Zacks Consensus Estimate of $130M and was up 17% fY/Y.
For FY 2025, management guided:
- Revenue of $875M to $900M, up from the prior $825M to $850M.
- Operating loss of $275M to $300M, improved from the prior loss of $300M to $325M.
CEO Brett P. Monia, Ph.D., commented: "The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines.
"With two independent launches now underway, and two more anticipated in 2026, we are delivering on our goal to bring a steady cadence of new medicines to people in need.
“Last month, we announced groundbreaking, positive topline Phase 3 results for olezarsen in severe hypertriglyceridemia and for zilganersen in Alexander disease, with regulatory filings planned in the coming months.
"Our approved and late-stage portfolio continues to deliver, positioning Ionis for substantial growth while, most importantly, offering the opportunity to profoundly improve the lives of people with serious diseases."
Yaron Werber, a top 28% analyst from TD Cowen maintains IONS with a strong buy rating and raises their IONS price target from $59.00 to $99.00, on Oct 30, 2025.
Michael Ulz, a top 9% analyst from Morgan Stanley maintains IONS with a strong buy rating and raises their IONS price target from $90.00 to $94.00, on Oct 30, 2025.
Gena Wang, a top 25% analyst from Barclays maintains IONS with a strong buy rating and raises their IONS price target from $80.00 to $95.00, on Oct 30, 2025.
Gary Nachman, a top 35% analyst from Raymond James reiterates IONS with a strong buy rating and raises their IONS price target from $85.00 to $89.00, on Oct 30, 2025.
You can dive deeper into what analysts are forecasting on the Ionis Pharmaceuticals stock forecast page.
Metrics for Advanced IONS Traders
Is IONS Growing Revenue?
Last year, IONS revenue was $966.96M. Over the past 5 year, IONS's revenue has increased by 0.72% per year. This was slower than the Biotechnology industry average of 43.17%.
Find out more about IONS's earnings and revenue performance here.
Are IONS executives and large shareholders buying or selling the stock?
In the last year, insiders at IONS have sold more shares than they have bought.
Shannon L. Devers, EVP Chief Human Resources Ofc of IONS, was the latest IONS insider to sell. They sold $323,489.18 worth of IONS shares on Jan 22, 2026.
Get more info about who owns IONS shares here.
Can I get consistent income from IONS stock?
No, Ionis Pharmaceuticals doesn't provide an income stream by paying out dividends.
IONS Social Trading Data
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your IONS buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, use a limit order.
Click the Open button and eToro will place your order.
If you require more help investing in stocks on eToro, watch the how to video below:
Step 6: Get the latest news on your investment in IONS
Now that you own some shares in IONS, you'll want to keep up with your new investment.
Add IONS to a watchlist to keep tabs on your IONS stock.
IONS Feed
How to Buy Stock in Ionis Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Ionis Pharmaceuticals stock right now:
- Figure out where to buy Ionis Pharmaceuticals stock
- Create a brokerage account
- Fund your brokerage account
- Research Ionis Pharmaceuticals stock
- Execute your IONS buy order
- Get the latest news on your investment in IONS
If you require a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep track of your investment in Ionis Pharmaceuticals, click below.
Other Articles You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.